Evaluation of cytology and HPV testing for testing for anal intraepithelial neoplasia in high-risk populations in the UK

Evaluation of cytology and HPV testing for testing for anal intraepithelial neoplasia in high-risk populations in the UK: a non-randomised study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN69055668

Enrollment

1000

Registered

2012-09-21

Start date

2012-09-01

Completion date

Unknown

Last updated

2017-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Topic: Infection, Generic Health Relevance and Cross Cutting Themes

Interventions

Anal cytology: All participants will be offered testing for evidence of abnormality including anal cytology (liquid based cytology), HPV testing, anal HPV testing.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. HIV positive men and women who have anal intercourse attending NHS genitourinary medicine (GUM) clinics 2. Men who have sex with men (MSM), recruited through GUM clinics and specialist general practices 3. Immunosuppressed transplant recipients (men and women) attending transplant follow-up clinics

Exclusion criteria

Exclusion criteria: Patients with prior history of anal neoplasia

Design outcomes

Primary

Measure	Time frame
Evaluation of LBC and HPV testing/typing and anoscopy as potential screening tests at end of study	—

Secondary

Measure	Time frame
1. Feasibility of recruitment, screening and follow up 2. Patient acceptability of screening for anal neoplasia 3. Reliable estimates of prevalence of anal cytological abnormality and HPV positivity by type Measured at end of study	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026